201 | Aditya Birla Sun Life AMC IPO Analysis by InvestorGain.com | InvestorGain.com | Apply | IPO |
202 | Paras Defence and Space Technologies IPO Analysis by Arihant Capital Markets Ltd | Arihant Capital Markets Ltd | Apply | IPO |
203 | Paras Defence and Space Technologies IPO Analysis by Arun Kejriwal | Arun Kejriwal | Apply | IPO |
204 | Paras Defence and Space Technologies IPO Analysis by Ashika Research | Ashika Research | Neutral | IPO |
205 | Paras Defence and Space Technologies IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
206 | Paras Defence and Space Technologies IPO Analysis by Canara Bank | Canara Bank | Apply | IPO |
207 | Paras Defence and Space Technologies IPO Analysis by Capital Market | Capital Market | May apply | IPO |
208 | Paras Defence and Space Technologies IPO Analysis by Choice Equity Broking Pvt Ltd | Choice Equity Broking Pvt Ltd | Apply | IPO |
209 | Paras Defence IPO review | Dilip Davda | May apply | IPO |
210 | Paras Defence and Space Technologies IPO Analysis by Edelweiss Broking Ltd | Edelweiss Broking Ltd | Neutral | IPO |
211 | Paras Defence and Space Technologies IPO Analysis by Hem Securities | Hem Securities | Apply | IPO |
212 | Paras Defence and Space Technologies IPO Analysis by ICICI Direct | ICICI Direct | Neutral | IPO |
213 | Paras Defence and Space Technologies IPO Analysis by Investmentz Ltd | Investmentz Ltd | Apply | IPO |
214 | Paras Defence and Space Technologies IPO Analysis by JM Financial Institutional Securities | JM Financial Institutional Securities | Neutral | IPO |
215 | Paras Defence and Space Technologies IPO Analysis by Marwadi Shares and Finance Limited | Marwadi Shares and Finance Ltd | Apply | IPO |
216 | Paras Defence and Space Technologies IPO Analysis by Reliance Securities | Reliance Securities | Neutral | IPO |
217 | Paras Defence and Space Technologies IPO Analysis by Religare Broking Limited | Religare Broking Limited | Neutral | IPO |
218 | Paras Defence and Space Technologies IPO Analysis by StockEdge | StockEdge | Neutral | IPO |
219 | Paras Defence and Space Technologies IPO Analysis by InvestorGain.com | InvestorGain.com | Apply | IPO |
220 | Paras Defence and Space Technologies IPO Analysis by Ventura Securities Limited | Ventura Securities Limited | Apply | IPO |
221 | Sansera Engineering IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
222 | Sansera Engineering IPO Analysis by BP Equities (BP Wealth) | BP Equities (BP Wealth) | Apply | IPO |
223 | Sansera Engineering IPO Analysis by Capital Market | Capital Market | Avoid | IPO |
224 | Sansera Engineering IPO Analysis by Choice Equity Broking Pvt Ltd | Choice Equity Broking Pvt Ltd | Apply | IPO |
225 | Sansera Engineering IPO review | Dilip Davda | Apply | IPO |
226 | Sansera Engineering IPO Analysis by ICICI Direct | ICICI Direct | Neutral | IPO |
227 | Sansera-Engineering IPO Analysis by JM Financial Institutional Securities | JM Financial Institutional Securities | Neutral | IPO |
228 | Sansera Engineering IPO Analysis by Kotak Securities | Kotak Securities | Neutral | IPO |
229 | Sansera Engineering IPO Analysis by Marwadi Shares and Finance Limited | Marwadi Shares and Finance Ltd | Apply | IPO |
230 | Sansera-Engineering-Ltd-IPO-Note-Religare-Broking | Religare Broking Limited | Neutral | IPO |
231 | Sansera Engineering IPO Analysis by SMC Global | SMC Global | Neutral | IPO |
232 | Vijaya Diagnostic IPO Analysis by Arihant Capital Markets Ltd | Arihant Capital Markets Ltd | Apply | IPO |
233 | Vijaya Diagnostic IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
234 | Vijaya Diagnostic IPO Analysis by Capital Market | Capital Market | Avoid | IPO |
235 | Vijaya Diagnostic IPO review | Dilip Davda | May apply | IPO |
236 | Vijaya Diagnostic IPO Analysis by HDFC Securities Limited | HDFC Securities Limited | Neutral | IPO |
237 | Vijaya Diagnostic IPO Analysis by Hem Securities | Hem Securities | Apply | IPO |
238 | Vijaya Diagnostic IPO Analysis by IIFL Securities | IIFL Securities | Apply | IPO |
239 | Vijaya Diagnostic IPO Analysis by JM Financial Institutional Securities | JM Financial Institutional Securities | Neutral | IPO |
240 | Vijaya Diagnostic IPO Analysis by Kotak Securities | Kotak Securities | Neutral | IPO |
241 | Vijaya Diagnostic IPO Analysis by KR Choksey Securities Ltd | KR Choksey Securities Ltd | Apply | IPO |
242 | Vijaya Diagnostic IPO Analysis by Marwadi Shares and Finance Limited | Marwadi Shares and Finance Ltd | Apply | IPO |
243 | Vijaya Diagnostic IPO Analysis by Mehta Equities | Mehta Equities | Apply | IPO |
244 | Vijaya Diagnostic IPO Analysis by Reliance Securities | Reliance Securities | Apply | IPO |
245 | Vijaya Diagnostic IPO Analysis by Religare Broking Limited | Religare Broking Limited | Neutral | IPO |
246 | Vijaya Diagnostic IPO Analysis by InvestorGain.com | InvestorGain.com | Avoid | IPO |
247 | Vijaya Diagnostic IPO Analysis by Ventura Securities Limited | Ventura Securities Limited | Apply | IPO |
248 | Ami Organics IPO Analysis by Anand Rathi | Anand Rathi | Apply | IPO |
249 | Ami Organics IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
250 | Ami Organics IPO Analysis by Capital Market | Capital Market | May apply | IPO |
251 | Ami Organics IPO review | Dilip Davda | May apply | IPO |
252 | Ami Organics IPO Analysis by Investmentz Ltd | Investmentz Ltd | Apply | IPO |
253 | Ami Organics IPO Analysis by Kotak Securities | Kotak Securities | Neutral | IPO |
254 | Ami Organics IPO Analysis by Marwadi Shares and Finance Limited | Marwadi Shares and Finance Ltd | Apply | IPO |
255 | Ami Organics IPO Analysis by Motilal Oswal | Motilal Oswal | Apply | IPO |
256 | Ami Organics IPO Analysis by StockEdge | StockEdge | Neutral | IPO |
257 | Ami Organics IPO Analysis by InvestorGain.com | InvestorGain.com | Apply | IPO |
258 | Aptus Value Housing Finance IPO Analysis by Arun Kejriwal | Arun Kejriwal | Avoid | IPO |
259 | Aptus Value Housing Finance IPO Analysis by Ashika Research | Ashika Research | Apply | IPO |
260 | Aptus Value Housing Finance IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
261 | Aptus Value Housing Finance IPO Analysis by Capital Market | Capital Market | May apply | IPO |
262 | Aptus Value Housing Finance IPO Analysis by Choice Equity Broking Pvt Ltd | Choice Equity Broking Pvt Ltd | May apply | IPO |
263 | Aptus Value IPO review | Dilip Davda | May apply | IPO |
264 | Aptus Value Housing Finance IPO Analysis by Edelweiss Broking Ltd | Edelweiss Broking Ltd | Neutral | IPO |
265 | Aptus Value Housing Finance IPO Analysis by HDFC Securities Limited | HDFC Securities Limited | Neutral | IPO |
266 | Aptus Value Housing Finance IPO Analysis by Hem Securities | Hem Securities | Apply | IPO |
267 | Aptus Value Housing Finance IPO Analysis by ICICI Direct | ICICI Direct | Neutral | IPO |
268 | Aptus Value Housing Finance IPO Analysis by Religare Broking Limited | Religare Broking Limited | Neutral | IPO |
269 | Aptus Value Housing Finance IPO Analysis by Ventura Securities Limited | Ventura Securities Limited | Neutral | IPO |
270 | Chemplast Sanmar IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
271 | Chemplast Sanmar IPO Analysis by Capital Market | Capital Market | Avoid | IPO |
272 | Chemplast Sanmar IPO review | Dilip Davda | May apply | IPO |
273 | Chemplast Sanmar IPO Analysis by Edelweiss Broking Ltd | Edelweiss Broking Ltd | Neutral | IPO |
274 | Chemplast Sanmar IPO Analysis by InvestorGain.com | InvestorGain.com | Avoid | IPO |
275 | Nuvoco IPO Analysis by Angel One | Angel One | Apply | IPO |
276 | Nuvoco IPO Analysis by Arun Kejriwal | Arun Kejriwal | May apply | IPO |
277 | Nuvoco IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
278 | Nuvoco IPO Analysis by Canara Bank | Canara Bank | Apply | IPO |
279 | Nuvoco IPO Analysis by Capital Market | Capital Market | Avoid | IPO |
280 | Nuvoco Vistas IPO review | Dilip Davda | May apply | IPO |
281 | Nuvoco IPO Analysis by Edelweiss Broking Ltd | Edelweiss Broking Ltd | Neutral | IPO |
282 | Nuvoco IPO Analysis by HDFC Securities Limited | HDFC Securities Limited | Neutral | IPO |
283 | Nuvoco IPO Analysis by Hem Securities | Hem Securities | Apply | IPO |
284 | Nuvoco IPO Analysis by ICICI Direct | ICICI Direct | Neutral | IPO |
285 | Nuvoco IPO Analysis by IDBI Capital | IDBI Capital | Apply | IPO |
286 | Nuvoco IPO Analysis by Investmentz Ltd | Investmentz Ltd | Apply | IPO |
287 | Nuvoco IPO Analysis by KR Choksey Securities Ltd | KR Choksey Securities Ltd | Apply | IPO |
288 | Nuvoco IPO Analysis by InvestorGain.com | InvestorGain.com | Avoid | IPO |
289 | CarTrade Tech IPO Analysis by Anand Rathi | Anand Rathi | Apply | IPO |
290 | CarTrade Tech IPO Analysis by Arun Kejriwal | Arun Kejriwal | Apply | IPO |
291 | CarTrade Tech IPO Analysis by Ashika Research | Ashika Research | Apply | IPO |
292 | CarTrade Tech IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
293 | CarTrade Tech IPO Analysis by BP Equities (BP Wealth) | BP Equities (BP Wealth) | Apply | IPO |
294 | CarTrade Tech IPO Analysis by Canara Bank | Canara Bank | Avoid | IPO |
295 | CarTrade Tech IPO Analysis by Capital Market | Capital Market | May apply | IPO |
296 | CarTrade Tech IPO review | Dilip Davda | May apply | IPO |
297 | CarTrade Tech IPO Analysis by Edelweiss Broking Ltd | Edelweiss Broking Ltd | Neutral | IPO |
298 | CarTrade Tech IPO Analysis by HDFC Securities Limited | HDFC Securities Limited | Neutral | IPO |
299 | CarTrade Tech IPO Analysis by Hem Securities | Hem Securities | Apply | IPO |
300 | CarTrade Tech IPO Analysis by ICICI Direct | ICICI Direct | Apply | IPO |
301 | CarTrade Tech IPO Analysis by Investmentz Ltd | Investmentz Ltd | Apply | IPO |
302 | CarTrade Tech IPO Analysis by JM Financial Institutional Securities | JM Financial Institutional Securities | Neutral | IPO |
303 | CarTrade Tech IPO Analysis by Motilal Oswal | Motilal Oswal | Apply | IPO |
304 | CarTrade Tech IPO Analysis by Nirmal Bang | Nirmal Bang | Apply | IPO |
305 | CarTrade Tech IPO Analysis by InvestorGain.com | InvestorGain.com | Apply | IPO |
306 | CarTrade Tech IPO Analysis by Ventura Securities Limited | Ventura Securities Limited | Neutral | IPO |
307 | Krsnaa Diagnostics IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
308 | Krsnaa Diagnostics IPO Analysis by Capital Market | Capital Market | Avoid | IPO |
309 | Krsnaa Diagno IPO review | Dilip Davda | May apply | IPO |
310 | Krsnaa Diagnostics IPO Analysis by Hem Securities | Hem Securities | Apply | IPO |
311 | Krsnaa Diagnostics IPO Analysis by JM Financial Institutional Securities | JM Financial Institutional Securities | Neutral | IPO |
312 | Krsnaa Diagnostics IPO Analysis by KR Choksey Securities Ltd | KR Choksey Securities Ltd | Apply | IPO |
313 | Krsnaa Diagnostics IPO Analysis by InvestorGain.com | InvestorGain.com | Apply | IPO |
314 | Devyani International IPO Analysis by Angel One | Angel One | Apply | IPO |
315 | Devyani International IPO Analysis by Arun Kejriwal | Arun Kejriwal | Apply | IPO |
316 | Devyani International IPO Analysis by Ashika Research | Ashika Research | Apply | IPO |
317 | Devyani International IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
318 | Devyani International IPO Analysis by BP Equities (BP Wealth) | BP Equities (BP Wealth) | Apply | IPO |
319 | Devyani International IPO Analysis by Canara Bank | Canara Bank | Apply | IPO |
320 | Devyani International IPO Analysis by Capital Market | Capital Market | May apply | IPO |
321 | Devyani International IPO Analysis by Choice Equity Broking Pvt Ltd | Choice Equity Broking Pvt Ltd | Apply | IPO |
322 | Devyani Intl IPO review | Dilip Davda | May apply | IPO |
323 | Devyani International IPO Analysis by ICICI Direct | ICICI Direct | Apply | IPO |
324 | Devyani International IPO Analysis by Investmentz Ltd | Investmentz Ltd | Apply | IPO |
325 | Devyani International IPO Analysis by JM Financial Institutional Securities | JM Financial Institutional Securities | Neutral | IPO |
326 | Devyani International IPO Analysis by Nirmal Bang | Nirmal Bang | Apply | IPO |
327 | Devyani International IPO Analysis by Prabhudas Lilladher Pvt Ltd | Prabhudas Lilladher Pvt Ltd | Apply | IPO |
328 | Devyani International IPO Analysis by Religare Broking Limited | Religare Broking Limited | Neutral | IPO |
329 | Devyani International IPO Analysis by Sharekhan Limited | Sharekhan Limited | Neutral | IPO |
330 | Exxaro Tiles IPO Analysis by Arihant Capital Markets Ltd | Arihant Capital Markets Ltd | Apply | IPO |
331 | Exxaro Tiles IPO Analysis by Arun Kejriwal | Arun Kejriwal | May apply | IPO |
332 | Exxaro Tiles IPO Analysis by AUM Capital Ltd | AUM Capital Ltd | Neutral | IPO |
333 | Exxaro Tiles IPO Analysis by Canara Bank | Canara Bank | Apply | IPO |
334 | Exxaro Tiles IPO Analysis by Capital Market | Capital Market | May apply | IPO |
335 | Exxaro Tiles IPO review | Dilip Davda | May apply | IPO |
336 | Exxaro Tiles IPO Analysis by Hem Securities | Hem Securities | Apply | IPO |
337 | Exxaro Tiles IPO Analysis by JM Financial Institutional Securities | JM Financial Institutional Securities | Neutral | IPO |
338 | Exxaro Tiles IPO Analysis by Reliance Securities | Reliance Securities | Neutral | IPO |
339 | Exxaro Tiles IPO Analysis by SMC Global | SMC Global | Apply | IPO |
340 | Windlas Biotech IPO Analysis by Capital Market | Capital Market | Avoid | IPO |
341 | Windlas Bio IPO review | Dilip Davda | May apply | IPO |
342 | Windlas Biotech IPO Analysis by JM Financial Institutional Securities | JM Financial Institutional Securities | Neutral | IPO |
343 | Windlas Biotech IPO Analysis by InvestorGain.com | InvestorGain.com | Apply | IPO |
344 | Rolex Rings IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
345 | Rolex Rings IPO Analysis by Capital Market | Capital Market | May apply | IPO |
346 | Rolex Rings IPO review | Dilip Davda | Apply | IPO |
347 | Rolex Rings IPO Analysis by Hem Securities | Hem Securities | Apply | IPO |
348 | Rolex Rings IPO Analysis by ICICI Direct | ICICI Direct | Apply | IPO |
349 | Rolex Rings IPO Analysis by KR Choksey Securities Ltd | KR Choksey Securities Ltd | Apply | IPO |
350 | Rolex Rings IPO Analysis by Reliance Securities | Reliance Securities | Apply | IPO |
351 | Rolex Rings IPO Analysis by Ventura Securities Limited | Ventura Securities Limited | Apply | IPO |
352 | Glenmark Life Sciences IPO Analysis by Anand Rathi | Anand Rathi | Apply | IPO |
353 | Glenmark Life Sciences IPO Analysis by Ashika Research | Ashika Research | Apply | IPO |
354 | Glenmark Life Sciences IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
355 | Glenmark Life Sciences IPO Analysis by Capital Market | Capital Market | May apply | IPO |
356 | Glenmark Life Sciences IPO Analysis by Choice Equity Broking Pvt Ltd | Choice Equity Broking Pvt Ltd | Apply | IPO |
357 | Glenmark Life IPO review | Dilip Davda | May apply | IPO |
358 | Glenmark Life Sciences IPO Analysis by Dolat Analysis and Research | Dolat Analysis and Research | Apply | IPO |
359 | Glenmark Life Sciences IPO Analysis by GEPL Capital Ltd | GEPL Capital Ltd | Apply | IPO |
360 | Glenmark Life Sciences IPO Analysis by HDFC Securities Limited | HDFC Securities Limited | Neutral | IPO |
361 | Glenmark Life Sciences IPO Analysis by ICICI Direct | ICICI Direct | Apply | IPO |
362 | Glenmark Life Sciences IPO Analysis by Investmentz Ltd | Investmentz Ltd | Apply | IPO |
363 | Glenmark Life Sciences IPO Analysis by SMC Global | SMC Global | May apply | IPO |
364 | Glenmark Life Sciences IPO Analysis by Sushil Finance Ltd | Sushil Finance Ltd | Apply | IPO |
365 | Glenmark Life Sciences IPO Analysis by InvestorGain.com | InvestorGain.com | Apply | IPO |
366 | Glenmark Life Sciences IPO Analysis by Ventura Securities Limited | Ventura Securities Limited | Apply | IPO |
367 | Tatva Chintan Pharma IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
368 | Tatva Chintan Pharma IPO Analysis by Capital Market | Capital Market | May apply | IPO |
369 | Tatva Chintan IPO review | Dilip Davda | Apply | IPO |
370 | Tatva Chintan Pharma IPO Analysis by Investmentz Ltd | Investmentz Ltd | Apply | IPO |
371 | Tatva Chintan Pharma IPO Analysis by KR Choksey Securities Ltd | KR Choksey Securities Ltd | Apply | IPO |
372 | Tatva Chintan Pharma IPO Analysis by Motilal Oswal | Motilal Oswal | Apply | IPO |
373 | Tatva Chintan Pharma IPO Analysis by Reliance Securities | Reliance Securities | Apply | IPO |
374 | Tatva Chintan Pharma IPO Analysis by Sharekhan Limited | Sharekhan Limited | Neutral | IPO |
375 | Tatva Chintan Pharma IPO Analysis by InvestorGain.com | InvestorGain.com | Apply | IPO |
376 | Tatva Chintan Pharma IPO Analysis by Ventura Securities Limited | Ventura Securities Limited | Apply | IPO |
377 | Zomato IPO Analysis by Ambit Capital Pvt Ltd | Ambit Capital Pvt Ltd | Neutral | IPO |
378 | Zomato IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
379 | Zomato IPO Analysis by Capital Market | Capital Market | May apply | IPO |
380 | Zomato IPO Analysis by Choice Equity Broking Pvt Ltd | Choice Equity Broking Pvt Ltd | May apply | IPO |
381 | Zomato IPO review | Dilip Davda | Avoid | IPO |
382 | Zomato IPO Analysis by GEPL Capital Ltd | GEPL Capital Ltd | Apply | IPO |
383 | Zomato IPO Analysis by ICICI Securities | ICICI Securities | Neutral | IPO |
384 | Zomato IPO Analysis by KR Choksey Securities Ltd | KR Choksey Securities Ltd | Apply | IPO |
385 | Zomato IPO Analysis by Religare Broking Limited | Religare Broking Limited | Neutral | IPO |
386 | Zomato IPO Analysis by Sharekhan Limited | Sharekhan Limited | Neutral | IPO |
387 | Zomato IPO Analysis by Ventura Securities Limited | Ventura Securities Limited | Apply | IPO |
388 | Clean Science IPO Analysis by Aditya Birla Ltd | Aditya Birla Ltd | Apply | IPO |
389 | Clean Science IPO Analysis by Angel One | Angel One | Apply | IPO |
390 | Clean Science IPO Analysis by Ashika Research | Ashika Research | Apply | IPO |
391 | Clean Science IPO Analysis by Axis Capital | Axis Capital | Not Rated | IPO |
392 | Clean Science IPO Analysis by BP Equities (BP Wealth) | BP Equities (BP Wealth) | Apply | IPO |
393 | Clean Science IPO Analysis by Canara Bank | Canara Bank | Apply | IPO |
394 | Clean Science IPO Analysis by Capital Market | Capital Market | Apply | IPO |
395 | Clean Science IPO review | Dilip Davda | May apply | IPO |
396 | Clean Science IPO Analysis by GEPL Capital Ltd | GEPL Capital Ltd | Apply | IPO |
397 | Clean Science IPO Analysis by HDFC Securities Limited | HDFC Securities Limited | Neutral | IPO |
398 | Clean Science IPO Analysis by Hem Securities | Hem Securities | Apply | IPO |
399 | Clean Science IPO Analysis by ICICI Direct | ICICI Direct | Apply | IPO |
400 | Clean Science IPO Analysis by IIFL Securities | IIFL Securities | Apply | IPO |
First Prev 2 of 4 Next Last |